MA53125A - Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée - Google Patents
Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevéeInfo
- Publication number
- MA53125A MA53125A MA053125A MA53125A MA53125A MA 53125 A MA53125 A MA 53125A MA 053125 A MA053125 A MA 053125A MA 53125 A MA53125 A MA 53125A MA 53125 A MA53125 A MA 53125A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- high affinity
- affinity selective
- selective tgf
- tgf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862696752P | 2018-07-11 | 2018-07-11 | |
US201862718196P | 2018-08-13 | 2018-08-13 | |
US201862737534P | 2018-09-27 | 2018-09-27 | |
US201862758180P | 2018-11-09 | 2018-11-09 | |
US201962810263P | 2019-02-25 | 2019-02-25 | |
US201962827552P | 2019-04-01 | 2019-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53125A true MA53125A (fr) | 2021-05-19 |
Family
ID=67470735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053125A MA53125A (fr) | 2018-07-11 | 2019-07-11 | Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210122814A1 (fr) |
EP (1) | EP3820508A1 (fr) |
JP (1) | JP2021531254A (fr) |
KR (1) | KR20210058811A (fr) |
CN (1) | CN112996535A (fr) |
AU (1) | AU2019302679A1 (fr) |
BR (1) | BR112021000353A2 (fr) |
CA (1) | CA3105988A1 (fr) |
CL (1) | CL2021000073A1 (fr) |
CO (1) | CO2021000419A2 (fr) |
IL (1) | IL279914A (fr) |
MA (1) | MA53125A (fr) |
MX (1) | MX2021000347A (fr) |
PH (1) | PH12021550020A1 (fr) |
SG (1) | SG11202013231SA (fr) |
TW (1) | TW202005981A (fr) |
WO (1) | WO2020014460A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3677278T3 (da) | 2018-07-11 | 2022-01-10 | Scholar Rock Inc | Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf |
SG11202012464WA (en) | 2018-07-11 | 2021-01-28 | H Lee Moffitt Cancer Center And Research Institute Inc | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
CA3128042A1 (fr) | 2019-01-30 | 2020-08-06 | Scholar Rock, Inc. | Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations |
CR20220125A (es) | 2019-08-28 | 2022-05-04 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-tgf-beta 1 latente y métodos de uso |
KR20220139888A (ko) | 2020-01-11 | 2022-10-17 | 스칼러 락, 인크. | TGFβ 억제제 및 그의 용도 |
JP2023511255A (ja) | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | TGF-β阻害剤及びその使用 |
US20230146730A1 (en) * | 2020-03-19 | 2023-05-11 | Chugai Seiyaku Kabushiki Kaisha | Biomarkers for predicting the response to checkpoint inhibitors |
WO2022204581A2 (fr) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Inhibiteurs de tgf-bêta et leur utilisation |
EP4348260A2 (fr) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Inhibiteurs de tgf-bêta et leur utilisation thérapeutique |
KR20240022608A (ko) * | 2021-06-18 | 2024-02-20 | 젠자임 코포레이션 | 항-tgf-베타 항체 제형 및 이의 용도 |
WO2023288277A1 (fr) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Inhibiteurs spécifiques du complexe ltbp de tgfb1 et leurs utilisations |
CN113604214B (zh) * | 2021-08-09 | 2023-07-14 | 青岛大学 | 一种高稳定性溶瘤肽荧光探针及其制备方法和应用 |
CN116262137A (zh) * | 2021-12-14 | 2023-06-16 | 四川大学 | 一种同时杀伤肿瘤和改善免疫微环境的抗肿瘤联合用药物 |
CN114236137A (zh) * | 2021-12-17 | 2022-03-25 | 中山大学·深圳 | 一种转化生长因子β的体外检测试剂盒及其应用 |
CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1892296A1 (fr) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Production et sélection de protéines de liaison diversifiées recombinantes |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2405246A1 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees |
ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
EP0889964A1 (fr) | 1996-03-28 | 1999-01-13 | The Johns Hopkins University | Analogues solubles heterodimeres divalents et multivalents de proteines |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
CA2411374C (fr) | 2000-06-29 | 2012-10-30 | Abbott Laboratories | Anticorps a double specificite, procedes de fabrication et d'utilisation |
US7803553B2 (en) | 2003-09-04 | 2010-09-28 | Riken | Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β |
HUE042689T2 (hu) | 2005-02-08 | 2019-07-29 | Genzyme Corp | TGFbéta elleni antitestek |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
PE20100054A1 (es) | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
PT2780368T (pt) | 2011-11-14 | 2018-03-22 | Regeneron Pharma | Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a |
AR095240A1 (es) * | 2013-03-11 | 2015-09-30 | Genzyme Corp | ANTICUERPOS ANTI-TGF-b MODIFICADOS POR INGENIERÍA GENÉTICA Y FRAGMENTOS DE UNIÓN A ANTÍGENOS |
LT2981822T (lt) * | 2013-05-06 | 2020-12-28 | Scholar Rock, Inc. | Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai |
CA3005158A1 (fr) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations |
WO2016201282A2 (fr) | 2015-06-12 | 2016-12-15 | Ludwig Institute For Cancer Research Ltd | Anticorps spécifiques de tgf-bêta 3 et procédés et utilisations associés |
JP2018527903A (ja) | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Gdf11結合タンパク質およびその使用 |
CN113896790A (zh) | 2015-09-15 | 2022-01-07 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 |
US11643459B2 (en) | 2016-03-11 | 2023-05-09 | Scholar Rock, Inc. | TGFβ1-binding immunoglobulins and use thereof |
MX2019008197A (es) | 2017-01-06 | 2019-09-11 | Scholar Rock Inc | Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. |
WO2019023661A1 (fr) | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations |
-
2019
- 2019-07-11 EP EP19745926.6A patent/EP3820508A1/fr active Pending
- 2019-07-11 CN CN201980059305.0A patent/CN112996535A/zh active Pending
- 2019-07-11 BR BR112021000353-3A patent/BR112021000353A2/pt unknown
- 2019-07-11 KR KR1020217003926A patent/KR20210058811A/ko active Search and Examination
- 2019-07-11 MX MX2021000347A patent/MX2021000347A/es unknown
- 2019-07-11 TW TW108124516A patent/TW202005981A/zh unknown
- 2019-07-11 AU AU2019302679A patent/AU2019302679A1/en active Pending
- 2019-07-11 MA MA053125A patent/MA53125A/fr unknown
- 2019-07-11 US US17/258,771 patent/US20210122814A1/en active Pending
- 2019-07-11 WO PCT/US2019/041373 patent/WO2020014460A1/fr active Search and Examination
- 2019-07-11 SG SG11202013231SA patent/SG11202013231SA/en unknown
- 2019-07-11 CA CA3105988A patent/CA3105988A1/fr active Pending
- 2019-07-11 JP JP2021500434A patent/JP2021531254A/ja active Pending
-
2021
- 2021-01-03 IL IL279914A patent/IL279914A/en unknown
- 2021-01-04 PH PH12021550020A patent/PH12021550020A1/en unknown
- 2021-01-11 CL CL2021000073A patent/CL2021000073A1/es unknown
- 2021-01-18 CO CONC2021/0000419A patent/CO2021000419A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN112996535A (zh) | 2021-06-18 |
AU2019302679A1 (en) | 2021-02-11 |
KR20210058811A (ko) | 2021-05-24 |
IL279914A (en) | 2021-03-01 |
SG11202013231SA (en) | 2021-01-28 |
BR112021000353A2 (pt) | 2021-08-03 |
MX2021000347A (es) | 2021-04-19 |
WO2020014460A1 (fr) | 2020-01-16 |
CO2021000419A2 (es) | 2021-01-29 |
WO2020014460A8 (fr) | 2020-02-13 |
CA3105988A1 (fr) | 2020-01-16 |
JP2021531254A (ja) | 2021-11-18 |
CL2021000073A1 (es) | 2021-07-30 |
PH12021550020A1 (en) | 2021-09-13 |
EP3820508A1 (fr) | 2021-05-19 |
US20210122814A1 (en) | 2021-04-29 |
TW202005981A (zh) | 2020-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53125A (fr) | Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée | |
IL280290A (en) | IL2 agonists | |
MA52413A (fr) | Inhibiteurs de cd73 | |
MA51616A (fr) | Inhibiteurs d'adn-pk | |
DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
SG11202113046PA (en) | Affinity agents | |
DK3763882T3 (da) | Hurtigskifteranordning | |
MA56069A (fr) | Composition herbicide | |
EP3855271A4 (fr) | Dispositif de détermination d'itinéraire de déplacement et engin de chantier | |
EA202191471A1 (ru) | Противовоспалительные полипептиды | |
ZA202102590B (en) | Cast-in track system component bushing | |
CL2020003051S1 (es) | Interfaz de cargador. (divisional de solicitud 202000568) | |
DK3795444T3 (da) | Arbejdstog | |
EP4047890A4 (fr) | Dispositif d'évaluation de destination de routage, procédé d'évaluation de destination de routage, et programme | |
MA52934A (fr) | Composés inhibiteurs de l'oga | |
MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
DK3840144T3 (da) | Skifteanordningen | |
DK3781263T3 (da) | Farmaceutisk effektive forbindelser, der selektivt hæmmer myosin-2-isoformerne | |
DK3911592T3 (da) | Bevægelig hængekranindretning | |
MA53009A (fr) | Agents inhibiteurs d'ask1 | |
GB201820756D0 (en) | MJ's-vimana | |
IT201700035964A1 (it) | “divisorio per boiserie” | |
UA39660S (uk) | Ківш | |
DE112020000103A5 (de) | Spannbacken |